Orbis
Orbis Global Equity
Global Large-cap
Dec 2024 → Dec 2025
Our archive holds 5 letters from this strategy, behind 6 investment theses and positions in 6 companies. Every quote below is copied verbatim from the letter it came from.
5 letters in 2 years — follow all of Orbis for every strategy.
Its investment theses
- Alphabet Inc.Dec 2025Alphabet Inc. is a dominant search and AI platform with synergistic data assets, vertical integration, and attractive long-term upside that justified its reintroduction to the portfolio.
- Alnylam PharmaceuticalsSep 2025Alnylam Pharmaceuticals is a leading innovator in RNA-interference therapeutics, recently achieving regulatory approval for its best-in-class ATTR-CM treatment, Amvuttra, which is exceeding market expectations and positioning the company for profitability.
- CRISPR TherapeuticsSep 2025CRISPR Therapeutics is currently trading at a discount to its cash and the value of its approved therapy, Casgev, which targets sickle-cell disease and ß-thalassemia, despite its strong competitive position and growth potential.
- GenmabSep 2025Genmab is undervalued due to market overreaction to impending patent expirations, offering a unique opportunity to invest in a company with a strong drug discovery platform and late-stage assets while trading below the value of its approved medicines.
- InsmedSep 2025Insmed is poised for sustained profitability following the FDA approval of its bronchiectasis treatment, brensocatib, while also advancing its promising pipeline in respiratory diseases.
- CorpayDec 2024Corpay is a company that helps businesses manage expenses and pay vendors through a network of services, demonstrating strong financial performance and significant growth potential, while currently trading at a discount compared to the broader market.